Clinical Trial Update: Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update describing blinatumomab administration in Chinese pediatric participants with relapsed/refractory B-cell precursor acute lymphob…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Precursor Acute Lymphoblastic Leukemia

Drugs mentioned

• Blinatumomab (Blincyto) (blinatumomab)

Snippet

Sponsor: Amgen | Conditions: B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING